AngioDynamics and The PERT Consortium have announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent pulmonary embolism (PE) research.
A press release notes that the ALPHA-PE Research Fund is designed to support independent, physician-led research addressing critical evidence gaps in PE care, where a lack of real-world data often limits clinical decision-making. By enabling investigator-driven studies, the programme aims to accelerate the generation of clinically relevant evidence to inform care delivery and advance understanding of PE management.
Awards ranging from US$50,000 to US$750,000 over one to three years will be distributed, empowering both established and emerging investigators to pursue data-driven research focused on patient outcomes, workflow optimisation, or novel therapeutic approaches with the potential to improve real-world PE care.
Investigators interested in applying to the ALPHA-PE Research Fund are invited to submit a brief Letter of Intent outlining study objectives, design, and budget. Selected applicants will be invited to submit full proposals for review.
“We are incredibly excited about this collaboration and the opportunity it creates for the PE community,” said Amir Darki (Loyola University, Chicago, USA), co-chair of the National PERT Research Consortium. “Physician-led, investigator-driven research is essential to closing critical evidence gaps in pulmonary embolism care. The ALPHA-PE Research Fund represents a meaningful investment in supporting innovation, fostering collaboration, and advancing impactful research that will directly inform real-world practice and improve patient outcomes.”
“This initiative reflects our commitment to supporting the cardiovascular community in closing critical data gaps in pulmonary embolism care,” said Laura Piccinini, senior vice president and general manager, Cardiovascular & International at AngioDynamics. “By supporting investigator-led studies, we strengthen the evidence base for approaches that can improve patient outcomes and advance the standard of care.”
“Independent, physician-led research plays a critical role in generating real-world insight in treating pulmonary embolism,” said Juan Carlos Serna, senior vice president of Scientific & Clinical Affairs at AngioDynamics. “The ALPHA-PE Research Fund is designed to foster science-driven collaboration that advances understanding and care for patients.”
